Mumbai based Supriya Lifescience, a major CGMP-compliant API manufacturer with a diverse range of therapeutics comprising antihistamines, anti-allergics, vitamins, and anesthetics, announced strong financial success in its unaudited Q2 FY25 results. The company's sales climbed by 18.6% year over year (YoY), reaching Rs. 166.1 crore, thanks to increasing market share in Europe and segmental contributions from the analgesic and anaesthetic categories.

In a statement released recently, the company stated that its gross profit for the second quarter of FY25 was Rs. 120.13 crore, up 53.1% from the second quarter of FY24. This development increased the company's EBITDA by 103.8% year over year, reaching Rs. 64.72 crore, with a significantly better EBITDA margin of 39.0%, up from 22.7% in the same quarter last year. Profit After Tax (PAT) for Q2 FY25 increased rapidly by 93.2% to Rs. 46.15 crore, bolstering the company's financial stability with a PAT margin improvement of nearly 1000 basis points to 27.8%.

Speaking about the encouraging results, Dr. Satish Wagh, executive chairman and whole-time director of Supriya Lifescience Ltd., emphasized the company's commitment to growth through innovation and strategic expansion. "Our commitment to innovation through R&D is paving the way for sustained growth and expansion," he told me. "With the commissioning of our advanced R&D lab at Lote Parshuram and the upcoming Ambernath facility, we're focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio."

The company's analgesic and anaesthetic division generated 54.9% of revenue in Q2 FY25, up from 50.0% in Q2 FY24, while the anti-asthmatic section expanded to 9.2% of total revenue. Supriya Lifescience is significantly growing its European market penetration, which now accounts for 45% of the company's sales in H1 FY25, up from 39% in H1 FY24.

Supriya Lifescience has expanded its customer base to over 1,700 in 128 countries, with the goal of expanding its global footprint. Its capacity utilization has risen dramatically, from 47% in FY22 to 86% in FY24, thanks to the recent capacity expansion. To further assist growth, the company purchased three land lots for future facility expansions.

With a recent exclusive 10-year deal with a European company, Supriya Lifescience is establishing itself as a dependable partner for complex chemical processes. Dr. Wagh stated that "this contract sets the stage for similar opportunities, underscoring our capabilities." The business intends to improve infrastructure and increase capacity at its Lote Parshuram facility to 1,020 KL by Q3 FY25.